絞り込み

16644

広告

「"Samama MM"[Author]」の検索結果

269件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Non-VKA oral anticoagulants: an update for the clinical bilogists.

Ex vivo reversal of the anticoagulant effects of edoxaban.

Pharmacology and Laboratory Testing of the Oral Xa Inhibitors.

[Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: Rivaroxaban, apixaban, edoxaban and betrixaban.]

Impact of age on the efficacy and safety of extended-duration thromboprophylaxis in medical patients. Subgroup analysis from the EXCLAIM randomised trial.

[Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013.]

Laboratory assessment of rivaroxaban: a review.

Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013.

[Hemorrhagic accidents of the new oral anticoagulants and coagulation assays.]

Laboratory testing of rivaroxaban in routine clinical practice: When, how, and which assays.

The Effects of the Antiplatelet Agents, Aspirin and Naproxen, on Pharmacokinetics and Pharmacodynamics of the Anticoagulant Edoxaban, a Direct Factor Xa Inhibitor.

Monitoring plasma levels of factor Xa inhibitors: how, why and when?

Which test to measure the anticoagulant effect of rivaroxaban? The anti-xa assay.

Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study.

Venous Thromboembolism Risk in Ischemic Stroke Patients Receiving Extended-Duration Enoxaparin Prophylaxis: Results From the EXCLAIM Study.

Massive transfusion: An overview of the main characteristics and potential risks associated with substances used for correction of a coagulopathy.

Pro- and anti-angiogenic agents.

[Skin necrosis during long-term fluindione treatment revealing protein C deficiency].

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
Sort by
※並べ替えは表示に時間がかかります